Edwards Lifesciences (NYSE: EW) enters accelerated share repurchase

Rhea-AI Filing Summary

Edwards Lifesciences Corporation reported that on August 19, 2025 it issued a press release announcing that the company entered into an accelerated share repurchase agreement. This type of agreement typically allows a company to buy back a significant number of its shares more quickly than through open-market repurchases, which can affect earnings per share and overall capital structure.

The press release describing the accelerated share repurchase is included as Exhibit 99.1 and is incorporated by reference, meaning the detailed terms and conditions are contained in that accompanying document rather than in this report.

Insights

Equity & Capital Allocation Analyst

Edwards Lifesciences enters an accelerated share repurchase, signaling a capital return move but without disclosed size here.

Edwards Lifesciences Corporation disclosed that it entered into an accelerated share repurchase (ASR) agreement, announced via a press release dated August 19, 2025 and filed as Exhibit 99.1. An ASR is a structured buyback in which a bank delivers a block of shares upfront, with the final share count adjusted over time based on the stock price.

The economic impact of this ASR depends heavily on its notional size, pricing terms, and duration, which are not described in this excerpt and instead reside in the press release. Without those details, it is difficult to gauge potential effects on share count, earnings per share, or balance sheet leverage. Subsequent company communications and financial statements will reflect how this repurchase flows through outstanding shares and overall capital allocation.

0001099800false00010998002025-08-192025-08-19

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 19, 2025

EDWARDS LIFESCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

1-15525

36-4316614

(State or other jurisdiction of incorporation)

(Commission file number)

(IRS Employer Identification No.)

One Edwards Way

Irvine, California 92614

(Address of principal executive offices and zip code)

(949) 250-2500

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $1.00 per share			EW			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On August 19, 2025, Edwards Lifesciences Corporation a Delaware corporation, issued a press release announcing its entry into an accelerated share repurchase agreement. A copy of the press release is filed as Exhibit 99.1, and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)						Exhibits
99.1						Press Release, issued on August 19, 2025, announcing Accelerated Share Repurchase Agreement.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						EDWARDS LIFESCIENCES CORPORATION
						By:			/s/ Scott B. Ullem
									Scott B. Ullem
Date: August 19, 2025									Chief Financial Officer

3

Exhibit Index

Exhibit Number						Description
99.1						Press Release, issued on August 19, 2025, announcing Accelerated Share Repurchase Agreement.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

4

FAQ

What did Edwards Lifesciences (EW) report in this Form 8-K?

Edwards Lifesciences Corporation reported that on August 19, 2025 it issued a press release announcing that it entered into an accelerated share repurchase agreement, and filed that press release as Exhibit 99.1.

What is the main purpose of the new agreement disclosed by Edwards Lifesciences (EW)?

The company disclosed that it entered into an accelerated share repurchase agreement, which is a structured arrangement for the company to repurchase its own common stock more quickly than through traditional open-market buybacks.

Where can investors find more details about Edwards Lifesciences’ accelerated share repurchase?

More detailed information is contained in the press release dated August 19, 2025, which is filed as Exhibit 99.1 and incorporated by reference into this report.

Does the 8-K for Edwards Lifesciences (EW) include financial statements?

No, this report lists only exhibits under Item 9.01, specifically Exhibit 99.1 for the press release about the accelerated share repurchase agreement and Exhibit 104 for the cover page interactive data file.

When was the accelerated share repurchase agreement for Edwards Lifesciences announced?

The company stated that the press release announcing the accelerated share repurchase agreement was issued on August 19, 2025.

Who signed the Edwards Lifesciences (EW) Form 8-K related to the accelerated share repurchase?

The report was signed on behalf of Edwards Lifesciences Corporation by Scott B. Ullem, Chief Financial Officer, dated August 19, 2025.